Abstract
In humans, T-cell development takes place in the thymus, which contains an external cortical region and an inner medulla. The skeleton of the thymus consists of stromal cells and is filled with thymocytes in different stages of differentiation. Thymocytes undergo to a development process before becoming mature T lymphocytes ready for export to the peripheral lymphoid organs. Classically, T-cell development has been reported to occur in four steps. First, bone marrow derived thymocytes that express neither CD4 nor CD8 surface antigens (double negative [DN] thymocytes) undergo an extensive phase of proliferation and differentiation and begin to express CD4 and CD8 (step 2: double positive [DP] thymocytes). During a subsequent negative selection process, approximately 5% of these DP cells undergo apoptosis. If these cells are not eliminated, they could differentiate into autoreactive lymphocytes, leading to the development of peripheral autoimmune diseases. In the thymus, a particular population of T regulatory (Treg) cells also develops. These Treg cells migrate to the periphery and are capable of suppressing autoreactive lymphocytes that may have escaped from the negative selection process. Autoimmune diseases are generally the result of insufficient negative selection of autoreactive cells in the thymus or a deficiency in Treg cell production or function. Future therapeutic strategies for autoimmune diseases should exploit manipulations in the negative selection process and/or the differentiation of Treg cells in the thymus.
Keywords: Thymus, apoptosis, autoimmunity, negative selection, glucocorticoids, mutant, lymphocytes, corticosteroids, thymectomy, Chemotherapy
Current Pharmaceutical Design
Title: Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases
Volume: 17 Issue: 29
Author(s): Domenico V. Delfino, Nicola Pozzesi, Sara Pierangeli, Emira Ayroldi and Alessandra Fierabracci
Affiliation:
Keywords: Thymus, apoptosis, autoimmunity, negative selection, glucocorticoids, mutant, lymphocytes, corticosteroids, thymectomy, Chemotherapy
Abstract: In humans, T-cell development takes place in the thymus, which contains an external cortical region and an inner medulla. The skeleton of the thymus consists of stromal cells and is filled with thymocytes in different stages of differentiation. Thymocytes undergo to a development process before becoming mature T lymphocytes ready for export to the peripheral lymphoid organs. Classically, T-cell development has been reported to occur in four steps. First, bone marrow derived thymocytes that express neither CD4 nor CD8 surface antigens (double negative [DN] thymocytes) undergo an extensive phase of proliferation and differentiation and begin to express CD4 and CD8 (step 2: double positive [DP] thymocytes). During a subsequent negative selection process, approximately 5% of these DP cells undergo apoptosis. If these cells are not eliminated, they could differentiate into autoreactive lymphocytes, leading to the development of peripheral autoimmune diseases. In the thymus, a particular population of T regulatory (Treg) cells also develops. These Treg cells migrate to the periphery and are capable of suppressing autoreactive lymphocytes that may have escaped from the negative selection process. Autoimmune diseases are generally the result of insufficient negative selection of autoreactive cells in the thymus or a deficiency in Treg cell production or function. Future therapeutic strategies for autoimmune diseases should exploit manipulations in the negative selection process and/or the differentiation of Treg cells in the thymus.
Export Options
About this article
Cite this article as:
V. Delfino Domenico, Pozzesi Nicola, Pierangeli Sara, Ayroldi Emira and Fierabracci Alessandra, Manipulating Thymic Apoptosis for Future Therapy of Autoimmune Diseases, Current Pharmaceutical Design 2011; 17 (29) . https://dx.doi.org/10.2174/138161211798157621
DOI https://dx.doi.org/10.2174/138161211798157621 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Emerging Indications for Statins: A Pluripotent Family of Agents with Several Potential Applications
Current Pharmaceutical Design The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Alternative Therapy in the Prevention of Experimental and Clinical Inflammatory Bowel Disease. Impact of Regular Physical Activity, Intestinal Alkaline Phosphatase and Herbal Products
Current Pharmaceutical Design The Role of Anaphylatoxins C3a and C5a in Regulating Innate and Adaptive Immune Responses
Inflammation & Allergy - Drug Targets (Discontinued) Personalized Therapies in Pediatric Inflammatory and Autoimmune Diseases
Current Pharmaceutical Design Targeted Therapies – Many Ways to (the Peace of) Rome
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Estrogens as Potential Therapeutic Agents in Multiple Sclerosis
Central Nervous System Agents in Medicinal Chemistry Infantile Epileptic Encephalopathy with Hypsarrhythmia (Infantile Spasms/West Syndrome) and Immunity
Central Nervous System Agents in Medicinal Chemistry Selective Binding BAFF/APRIL by the In and Outside Conservative Region of BCMA
Protein & Peptide Letters Alpha 4 Integrin Antagonists
Current Pharmaceutical Design Pulmonary Infections in the Era of Biological Agents
Current Respiratory Medicine Reviews Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Experimental Models of Relapsing-Remitting Multiple Sclerosis: Current Concepts and Perspective
Current Neurovascular Research Toward Small-Molecule Inhibition of Protein–Protein Interactions: General Aspects and Recent Progress in Targeting Costimulatory and Coinhibitory (Immune Checkpoint) Interactions
Current Topics in Medicinal Chemistry Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry Monocyte Dependent Regulation of Autoimmune Inflammation
Current Molecular Medicine Therapeutic Monitoring of Immunotherapies in Autoimmune Diseases
Current Pharmaceutical Design An Unusual Presentation of a Rare Scleroderma Mimic: What is Behind the Scenes?
Current Rheumatology Reviews Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design